Company intelligence / Profile preview

inQB8 Medical Technologies

Winchester, Massachusetts, United Statesinqb8medtech.com ↗

Ownership: Private
Development stage: Phase 1

Overview

inQB8’s MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) system has achieved successful first-in-human implantation for severe tricuspid regurgitation. The Relief Cardiovascular “Relief” system is preparing for its first-in-human feasibility study targeting heart failure patients with fluid overload by modulating renal vein pressures.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

MonarQ

Phase 1

Indications: Tricuspid regurgitation

Partnerships

Peijia Medical Limited—strategic partnership/acquisition of MonarQ technology; ongoing development collaboration on structural heart devices targeting global markets including China

Beyond the preview

Go deeper on inQB8 Medical Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on inQB8 Medical Technologies.

Explore the full profile